$INBP SEC Filings

Filed On	Filing
28 Oct 2026	Proxy statement: annual meeting on November 30, 2026 CEO pay $351K, up 7.9%
25 Sep 2026	8-K: Results of Operations and Financial Condition HILLSIDE, NEW JERSEY (September 25, 2026) - Integrated BioPharma, Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the quarter and fiscal year ended June 30, 2026.
25 Sep 2026	FORM 10-K
20 Aug 2026	8-K: Other Events
02 Jul 2026	8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
25 Jun 2026	Form 4: DeSantis Damon, Director Granted 50,000 Stock Option (Right to Buy)
25 Jun 2026	Form 4/A: Friedman Eric J, Director Granted 50,000 Stock Option (Right to Buy)
25 Jun 2026	Form 4: Friedman Eric J, Director Granted 50,000 Stock Option (Right to Buy)
25 Jun 2026	Form 4: Canarick Robert, Director Granted 50,000 Stock Option (Right to Buy)
25 Jun 2026	Form 4: Milmoe William H., Director Granted 50,000 Stock Option (Right to Buy)
08 May 2026	8-K: Results of Operations and Financial Condition
08 May 2026	FORM 10-Q
17 Apr 2026	SCHEDULE 13D/A
17 Apr 2026	SCHEDULE 13D
17 Apr 2026	Form 4/A: Milmoe William H., Director Gave 11,201,964 shares as a gift
17 Apr 2026	Form 4: Milmoe William H., Director Gave 11,201,964 shares as a gift
17 Apr 2026	Form 4: Desantis Carl, 10% owner Gave 11,201,964 shares as a gift
17 Apr 2026	Form 4: DeSantis Damon, Director Acquired 11,201,964 shares (Gift)
15 Apr 2026	8-K: Other Events
26 Mar 2026	Form 4: Desantis Carl, 10% owner Gave 1,363,685 shares as a gift

Comments